Summary
On the basis of previous observations indicating that the platinum (II)-doxorubicin complex (coordinated via the amino sugar) was active against resistant ascitic leukemias, the preclinical evaluation of this complex was extended to a variety of experimental tumors, including solid doxorubicin-resistant tumors (P388/DX, B16 melanoma with acquired resistance, and MXT mammary carcinoma with natural resistance). In the treatment of sensitive tumors (Gross leukemia and Lewis lung tumor) the complex provided efficacy comparable to that of doxorubicin. Among resistant models, only P388/DX, which is only weakly responsive to cisplatin itself, showed significant sensitivity to the platinum complex. Since all resistant tumors were transplanted in the same site (s.c.) of the same mouse strain, it is likely that the different tumor response reflects different underlying mechanisms of cell resistance rather than alterations in pharmacologic behavior of the anthracycline after covalent binding to platinum. The data reported in this preclinical study support the potential value of this approach to overcome selected manifestations of resistance to anthracyclines. In contrast to the highly toxic doxorubicin/cisplatin combination, doxorubicin complexation with platinum was not associated to an increase in toxicity.
Similar content being viewed by others
References
Pasini A, Zunino F: New cisplatin analogues. On the way to better antitumor agents. Angew Chem Int Ed Engl 26:615–624, 1987
Zunino F, Savi G, Pasini A: Synthesis and antitumor activity of a platinum(II)-doxorubicin complex. Cancer Chemother Pharmacol 18:180–182, 1986
Pasini A, Pratesi G, Savi G, Zunino F: A doxorubicin-Pt(II) complex. Chemistry and antitumor activity. Inorganica Chimica Acta 137:123–124, 1987
Schabel Jr FM, Skipper HE, Trader MW, Laster Jr WR, Griswold Jr DP, Corbett TH: Establishment of crossresistance profiles for new agents. Cancer Treat Rep 67:905, 1983
Supino R, Prosperi E, Formelli F, Mariani M, Parmiani G:Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. Br J Cancer 54:33, 1986
Formelli F, Cleris L, Carsana R: Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. Cancer Chemother Pharmacol 21:329–336, 1988
Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 3:2, 1972
Malinge JM, Schwartz A, Leng M: Characterization of the ternary complexes formed in the reaction of cis-diamminedichloroplatinum (II), ethidium bromide and nucleic acids. Nucl Acids Res 15:1779–1796, 1987
Bowler BE, Lippard SJ: Modulation of platinum antitumor drug binding to DNA by linked and free bintercalators. Biochemistry 25:3031–3038, 1986
Bowler BE, Ahmed KJ, Sundquist WI, Hollis LS, Whang EE, Lippard SJ: Synthesis, characterization, and DNAbinding propeties of (1,2-diaminoethane)platinum(II) complexes linked to the DNA intercalator acridine orange by trimethylene and hexamethylene chains. J Am Chem Soc 111:1299–1306, 1989
Kitov S, Ben-Shoshan R, Ringel I, Gibson D, Katzhendler J: The effect of cis-platin analogues derived from aminoalkylaminoanthraquinones on DNA cleavage: an electron microscopy study. Eur J Med Chem 23:381–383, 1988.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zunino, F., Pratesi, G., Formelli, F. et al. Evaluation of a platinum-doxorubicin complex in experimental tumor systems. Invest New Drugs 8, 341–345 (1990). https://doi.org/10.1007/BF00198589
Issue Date:
DOI: https://doi.org/10.1007/BF00198589